Publications by authors named "Vicky Coyle"

Claim this Profile
F
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.
Gary Middleton, Charlotte Gaskell, Joshua Savage, John Bridgewater, Paul Ross, Vicky Coyle

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of lifestyle interventions on sarcopenia in advanced colorectal cancer: A systematic review.
David Burke, Malcolm Brown, Conor O'Neill, Helen G Coleman, Tilman Kuhn, Vicky Coyle

J Geriatr Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prehabilitation provision and practice in the UK: a freedom of information survey.
Maria Pufulete, Vicky Coyle, Debbie Provan, Clare Shaw, Peter Kunzmann

Br J Anaesth· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Vicky M Coyle

J Exp Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes

Health Technol Assess· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial.
Vicky Coyle, Caroline Forde, Danny F McAuley, Richard H Wilson, Mike Clarke

Clin Microbiol Infect· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Kirsty Taylor, Jinfeng Zou, Marcos Magalhaes, Marc Oliva, Anna Spreafico, Vicky M Coyle

Eur J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Aya El Helali, Ruth Plummer, Gordon C Jayson, Vicky M Coyle, Yvette Drew

Br J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Nyree Crawford, Katie J Stott, Tamas Sessler, Christopher McCann, William McDaid, Vicky M Coyle

Mol Cancer Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary genetic algorithm identifies as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer.
Matthew Alderdice, Stephanie G Craig, Matthew P Humphries, Alan Gilmore, Nicole Johnston, Vicky Coyle

NAR Genom Bioinform· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.
Andrea Lees, Alexander J McIntyre, Nyree T Crawford, Fiammetta Falcone, Christopher McCann, Vicky M Coyle

Proc Natl Acad Sci U S A· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Caroline Forde, Ronan McMullan, Mike Clarke, Richard H Wilson, Ruth Plummer, Vicky Coyle

Trials· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Victoria K Woodcock, Sally Clive, Richard H Wilson, Vicky M Coyle, Michael R L Stratford

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Matthew Alderdice, Philip D Dunne, Aidan J Cole, Paul G O'Reilly, Darragh G McArt, Vicky M Coyle

Mod Pathol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
David Jamieson, Melanie J Griffin, Julieann Sludden, Yvette Drew, Nicola Cresti, Vicky Coyle

Eur J Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
Donna M Graham, Vicky M Coyle, Richard D Kennedy, Richard H Wilson

Curr Colorectal Cancer Rep· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Donna M Graham, Richard C Turkington, Manuel Salto-Tellez, Vicky M Coyle, Richard H Wilson

J Natl Cancer Inst· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic melanoma: a regional review and future directions.
Khurum H Khan, Rebecca B Goody, Hassan Hameed, Awais Jalil, Vicky M Coyle

Tumori· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
Wendy L Allen, Richard C Turkington, Leanne Stevenson, Gail Carson, Vicky M Coyle

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Wendy L Allen, Leanne Stevenson, Vicky M Coyle, Puthen V Jithesh, Irina Proutski

Mol Cancer Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic markers for decision making: what is preventing us from using markers?
Vicky M Coyle, Patrick G Johnston

Nat Rev Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiling of colorectal cancer.
Vicky M Coyle, Patrick G Johnston

Eur J Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical determinants of response to irinotecan-based therapy derived from cell line models.
Wendy L Allen, Vicky M Coyle, Puthen V Jithesh, Irina Proutski, Leanne Stevenson

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and prognostic markers in colorectal cancer.
Richard C Turkington, Vicky M Coyle, Patrick G Johnston, Martin M Eatock

Per Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.
Wendy L Allen, Estelle G McLean, John Boyer, Andrea McCulla, Peter M Wilson, Vicky Coyle

Mol Cancer Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis